Surufatinib: First Approval

Drugs. 2021 Apr;81(6):727-732. doi: 10.1007/s40265-021-01489-y.

Abstract

Surufatinib (Sulanda®), an oral angio-immuno kinase inhibitor that selectively targets VEGFR 1, 2, and 3, FGFR1 and CSF-1R, is being developed by HUTCHMED for the treatment of solid tumours, including neuroendocrine tumours (NETs). On 30 December 2020, surufatinib received its first approval in China for the treatment of late-stage, well-differentiated, extrapancreatic NET. Surufatinib is in preregistration in China for pancreatic NET and in the USA for pancreatic and extrapancreatic NET; phase II development is underway for other solid tumours, including thyroid cancer, biliary tract carcinoma and soft tissue sarcoma. This article summarizes the milestones in the development of surufatinib leading to this first approval for extrapancreatic NET.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • China
  • Humans
  • Indoles / administration & dosage
  • Indoles / chemistry
  • Indoles / pharmacology*
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / metabolism
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / metabolism
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrimidines / administration & dosage
  • Pyrimidines / chemistry
  • Pyrimidines / pharmacology*
  • Receptor, Fibroblast Growth Factor, Type 1 / antagonists & inhibitors
  • Receptor, Fibroblast Growth Factor, Type 1 / metabolism
  • Receptors, Granulocyte-Macrophage Colony-Stimulating Factor / antagonists & inhibitors
  • Receptors, Granulocyte-Macrophage Colony-Stimulating Factor / metabolism
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Receptors, Vascular Endothelial Growth Factor / metabolism
  • Sulfonamides / administration & dosage
  • Sulfonamides / chemistry
  • Sulfonamides / pharmacology*

Substances

  • Antineoplastic Agents
  • Indoles
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
  • Sulfonamides
  • surufatinib
  • Receptor, Fibroblast Growth Factor, Type 1
  • Receptors, Vascular Endothelial Growth Factor